2026 ODYSSEY Trial Studies

Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial

Recovery in BMD following recent repeat pregnancy and breastfeeding among African women with and without HIV

Hospitalization Rates and Associated Factors Among Older Adults With HIV in the United States